TargetBeta
PDE3A
phosphodiesterase 3A · also CGI-PDE · Phosphodiesterases
2 programs in company-led studies act on PDE3A, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Cilostazolrule | Otsuka | phase 4 | 290 running | – | ChEMBL |
| ensifentrinerule | Merck | phase 3 | 172 running | ALDH7A1, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D | ChEMBL |
Conditions their studies are in
- Angina Pectoris, Variant, 1 program
- Asthma, 1 program
- Cerebral Infarction, 1 program
- Cystic Fibrosis, 1 program
- Hypercholesterolemia, 1 program
- Intermittent Claudication, 1 program
- Pulmonary Disease, Chronic Obstructive, 1 program
- Raynaud Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 1, 2027ensifentrine · Merck · phase 3 · NCT05270525
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.